| 000 | 01707 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517094748.0 | ||
| 264 | 0 | _c20170509 | |
| 008 | 201705s 0 0 eng d | ||
| 022 | _a1873-264X | ||
| 024 | 7 |
_a10.1016/j.jpba.2016.04.030 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDing, X | |
| 245 | 0 | 0 |
_aValidation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS. _h[electronic resource] |
| 260 |
_bJournal of pharmaceutical and biomedical analysis _cJul 2016 |
||
| 300 |
_a117-23 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Validation Study | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xanalysis |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aCalibration |
| 650 | 0 | 4 |
_aChromatography, Liquid _xmethods |
| 650 | 0 | 4 |
_aChromatography, Reverse-Phase _xmethods |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 | _aDrug Storage |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xanalysis |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 |
_aOxazepines _xanalysis |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 |
_aSolid Phase Extraction _xmethods |
| 650 | 0 | 4 |
_aTandem Mass Spectrometry _xmethods |
| 650 | 0 | 4 | _aTemperature |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aFaber, K | |
| 700 | 1 | _aShi, Y | |
| 700 | 1 | _aMcKnight, J | |
| 700 | 1 | _aDorshorst, D | |
| 700 | 1 | _aWare, J A | |
| 700 | 1 | _aDean, B | |
| 773 | 0 |
_tJournal of pharmaceutical and biomedical analysis _gvol. 126 _gp. 117-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jpba.2016.04.030 _zAvailable from publisher's website |
| 999 |
_c26027652 _d26027652 |
||